Labarai

Ƙasa ba za ta iya yin kasadar tsofaffi ta hanyar sassauta manufofin COVID ba

Daga ZHANG ZHIHAO | CHINA DAILY | An sabunta: 2022-05-16 07:39

Ana duba hawan jinin wani dattijo kafin a yi masa allurarMaganin rigakafin cutar covid-19a gida a gundumar Dongcheng ta Beijing, 10 ga Mayu, 2022. [Hoto/Xinhua]

Wani babban kwararre kan cututtukan da ke yaduwa ya ce, samar da ingantaccen tsarin kula da sabbin masu fama da cutar da kuma hanyoyin kula da lafiya, gwajin da ya fi inganci da kuma sauƙin samu, da kuma maganin COVID-19 a gida, muhimman abubuwan da kasar Sin za ta bukata don daidaita manufofinta na yanzu don shawo kan cutar COVID.

Ba tare da waɗannan sharuɗɗan ba, kawar da cutar ta hanyar amfani da na'ura mai kwakwalwa ya kasance mafi kyawun dabarar da za ta iya ɗaukar nauyi ga China, domin ƙasar ba za ta iya yin kasada ga rayuwar tsofaffi ba ta hanyar sassauta matakan da take ɗauka na yaƙi da cutar ba da wuri, in ji Wang Guiqiang, shugaban sashen cututtuka masu yaɗuwa a Asibitin Farko na Jami'ar Peking.

Babban yankin kasar Sin ya bayar da rahoton mutane 226 da aka tabbatar sun kamu da cutar COVID-19 a ranar Asabar, inda 166 daga cikinsu suna Shanghai ne, yayin da 33 kuma suna Beijing, a cewar rahoton Hukumar Lafiya ta Kasa a ranar Lahadi.

A wani taron karawa juna sani na jama'a da aka gudanar a ranar Asabar, Wang, wanda shi ma memba ne na tawagar kwararru na kasa kan magance cutar COVID-19, ya ce barkewar cutar COVID-19 a Hong Kong da Shanghai kwanan nan ta nuna cewa bambancin Omicron na iya zama babbar barazana ga tsofaffi, musamman wadanda ba a yi musu allurar riga-kafi ba kuma suna da wasu matsalolin lafiya.

"Idan China na son sake budewa, sharadin farko shi ne a rage yawan mace-macen da ake samu sakamakon barkewar cutar COVID-19, kuma hanya mafi kyau ta yin hakan ita ce ta hanyar allurar riga-kafi," in ji shi.

Bayanan lafiyar jama'a na Yankin Gudanarwa na Musamman na Hong Kong sun nuna cewa ya zuwa ranar Asabar, jimillar mace-macen da annobar Omicron ta yi ya kai kashi 0.77 cikin 100, amma adadin ya karu zuwa kashi 2.26 cikin 100 ga wadanda ba su yi allurar riga-kafi ba ko kuma wadanda ba su kammala allurar rigakafin ba.

Jimillar mutane 9,147 ne suka mutu a sabon barkewar cutar a birnin zuwa ranar Asabar, yawancinsu tsofaffi ne 'yan shekara 60 zuwa sama. Ga waɗanda suka haura shekaru 80, adadin mace-macen ya kai kashi 13.39 cikin ɗari idan ba su karɓi ko kammala allurar rigakafin ba.

Hukumar Lafiya ta Kasa ta ce ya zuwa ranar Alhamis, sama da tsofaffi miliyan 228 da suka haura shekaru 60 a babban yankin kasar Sin an yi musu allurar riga-kafi, inda miliyan 216 daga cikinsu suka kammala cikakken shirin allurar riga-kafi, kuma kimanin tsofaffi miliyan 164 aka yi musu allurar kara karfin gwiwa. Hukumar Lafiya ta Kasa ta ce babban yankin kasar Sin yana da kimanin mutane miliyan 264 a wannan rukunin shekaru a watan Nuwamban 2020.

Kariya mai mahimmanci

"Fadada allurar riga-kafi da allurar rigakafi ga tsofaffi, musamman waɗanda suka haura shekaru 80, yana da matuƙar muhimmanci don kare su daga rashin lafiya mai tsanani da mutuwa," in ji Wang.

Kasar Sin ta riga ta fara samar da alluran rigakafi da aka tsara musamman don nau'in Omicron mai saurin yaduwa. A farkon wannan watan, China National Biotech Group, wani reshe na Sinopharm, ya fara gwajin asibiti don allurar rigakafin Omicron a Hangzhou, lardin Zhejiang.

Tunda kariyar rigakafin cutar coronavirus na iya raguwa akan lokaci, yana da matukar muhimmanci kuma mutane, ciki har da waɗanda aka yi musu allurar ƙarawa a baya, su sake samun ƙarfin garkuwar jikinsu ta hanyar amfani da allurar Omicron da zarar ta fito, in ji Wang.

Baya ga allurar riga-kafi, Wang ya ce yana da matukar muhimmanci a sami ingantaccen tsarin mayar da martani kan barkewar cutar COVID-19 don kare tsarin kiwon lafiyar kasar.

Misali, ya kamata a sami ƙa'idodi bayyanannu kan waɗanda da kuma yadda ya kamata a killace mutane a gida domin ma'aikatan al'umma su iya kula da kuma yi wa mutanen da aka killace hidima yadda ya kamata, kuma domin asibitoci kada su cika da yawan marasa lafiya da suka kamu da cutar.

"Yana da matukar muhimmanci asibitoci su samar da muhimman ayyukan kiwon lafiya ga sauran marasa lafiya a lokacin barkewar cutar COVID-19. Idan tarin sabbin marasa lafiya ya katse wannan aikin, zai iya haifar da asarar rayuka a kaikaice, wanda ba za a yarda da shi ba," in ji shi.

Ya kuma kara da cewa ma'aikatan al'umma ya kamata su ci gaba da bin diddigin halin da tsofaffi da kuma wadanda ke da bukatu na musamman na likitanci ke ciki, ta yadda ma'aikatan lafiya za su iya bayar da taimakon likita cikin gaggawa idan akwai bukata.

Bugu da ƙari, jama'a za su buƙaci magungunan kashe ƙwayoyin cuta masu araha da sauƙin samu, in ji Wang. Maganin rigakafin ƙwayoyin cuta na monoclonal da ake amfani da shi a yanzu yana buƙatar allurar rigakafi ta jijiyoyi a asibiti, kuma maganin COVID na Pfizer Paxlovid yana da farashi mai yawa na yuan 2,300 ($338.7).

"Ina fatan ƙarin magungunanmu, da kuma magungunan gargajiya na kasar Sin, za su iya taka muhimmiyar rawa wajen yaƙar annobar," in ji shi. "Idan muka sami damar samun magani mai ƙarfi da araha, to za mu sami kwarin gwiwar sake buɗewa."

Muhimman abubuwan da ake buƙata

A halin yanzu, inganta daidaiton kayan gwajin antigen cikin sauri da kuma fadada damar shiga da kuma iyawar gwajin nucleic acid a matakin al'umma suma muhimman abubuwan da ake bukata don sake budewa, in ji Wang.

"Gabaɗaya dai, yanzu ba lokaci ne da China za ta sake buɗewa ba. Sakamakon haka, muna buƙatar ɗaukar dabarun share fagen aiki da kuma kare tsofaffi waɗanda ke da matsalolin lafiya," in ji shi.

Lei Zhenglong, mataimakin darakta na Ofishin Rigakafi da Kula da Cututtuka na Hukumar Lafiya ta Kasa, ya sake nanata a ranar Juma'a cewa bayan ya yi fama da annobar COVID-19 sama da shekaru biyu, dabarun kawar da cutar sun tabbatar da cewa suna da tasiri wajen kare lafiyar jama'a, kuma wannan ita ce mafi kyawun zabi ga kasar Sin idan aka yi la'akari da halin da ake ciki a yanzu.